Crossmark

Current and Emerging Treatment Landscape of Common EGFR-Mutated Advanced Non-small Cell Lung Cancer

Crossref DOI link: https://doi.org/10.1007/s11523-025-01196-8

Published Online: 2026-01-29

Published Print: 2026-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

McMahon, David John https://orcid.org/0000-0001-5827-3464
John, Alexius

Popat, Sanjay https://orcid.org/0000-0002-5077-6814
License Information

Text and Data Mining valid from 2026-01-01

Version of Record valid from 2026-01-01
More Information

Article History

Received: 14 October 2025

Accepted: 30 December 2025

First Online: 29 January 2026

Declarations

:

: No external funding was used in the preparation of this article.

: David John McMahon has received institutional research funding from Roche and Pfizer, and travel expenses from Takeda. Alexius John has received honoraria from Boehringer Ingleheim and travel expenses from Takeda. Sanjay Popat has been a consultant and received honoraria from Anheart, Amgen, Arcus Biosciences, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Ellipses, Erasca, Gilead, GlaxoSmithKline, Guardant Health, IO Biotech, Janssen, Lilly, Merck KGaA, Mirati, MSD, Novocure, Novartis, Pfizer, PharmaMar, Pierre Fabre, Regeneron, Roche, Sanofi and Takeda; received direct funding from Medscape and VJ Oncology; has been an advisor for ALK Positive UK, Lung Cancer Europe and Ruth Strauss Foundation; and on the leadership team for BTOG Research Group and ETOP-IBCSG Foundation Board.

: Not applicable.

: Not applicable.

: Not applicable.

: No datasets were generated or analysed during the current study.

: Not applicable.

: DJM: conceptualisation, writing (review and editing), data curation. AJ: writing (review and editing). SP: conceptualisation, writing (review and editing), supervision.

Document is current

Any future updates will be listed below